United States Hemophilia Market Insight
Published: 25 July 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The United States Hemophilia Market is projected to grow at a CAGR of around 7.2% over the forecast period, driven by increasing adoption of advanced clotting factor therapies and comprehensive hemophilia care.
United States Hemophilia Market Forecasts to 2035
- The United States Hemophilia Market size was estimated at approximately USD 8.65 Billion in 2025.
- The market is expected to grow at a CAGR of around 7.2% from 2025 to 2035.
- The United States Hemophilia market is projected to reach approximately USD 17.30 Billion by 2035.
Notable Insights for the United States Hemophilia Market
- Segmentation based on therapy type indicates that Clotting Factor Replacement Therapy, Non-Factor Therapy, Gene Therapy, and Bypassing Agents account for nearly 87% of market revenue in 2025, supported by increasing adoption of long-acting treatments and innovative biologics.
- Segmentation based on disease type shows that Hemophilia A, Hemophilia B, Congenital Hemophilia, and Acquired Hemophilia collectively hold nearly 91% market share in 2025, driven by improved diagnosis and lifelong disease management.
- Growing adoption of recombinant clotting factors, extended half-life therapies, gene-editing technologies, digital patient monitoring, and personalized treatment protocols contributes to more than 62% of new technology deployments in 2025.
- Rising investments in gene therapy research, rare disease drug development, specialty treatment centers, home infusion programs, and precision medicine initiatives account for nearly 64% of new capital expenditure across the United States hemophilia industry.
Download the eBook (ToC)
Research Methodologies Used to Analyze United States Hemophilia Market
The United States Hemophilia Market is analyzed using primary and secondary research methodologies to ensure accurate market estimates and forecasts. Primary research includes interviews with hematologists, hospital specialists, pharmaceutical manufacturers, biotechnology companies, treatment center administrators, patient advocacy organizations, regulatory authorities, healthcare providers, and industry experts. Secondary research covers company annual reports, FDA publications, CDC reports, NIH databases, government healthcare statistics, scientific journals, industry association reports, clinical trial databases, and pharmaceutical market studies. Data triangulation, competitive benchmarking, pricing analysis, market share evaluation, regulatory assessment, epidemiological analysis, and statistical forecasting models are applied to validate findings and provide reliable market forecasts through 2035.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States Hemophilia Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Hemophilia Market
• Roche
• Pfizer Inc.
• Novo Nordisk A/S
• CSL Behring
• Takeda Pharmaceutical Company Limited
• Sanofi
• BioMarin Pharmaceutical Inc.
• Bayer AG
• Octapharma AG
• Grifols S.A.
Recent Developments:
- In May 2025, BioMarin Pharmaceutical expanded post-commercialization programs for its gene therapy portfolio, focusing on long-term patient monitoring and treatment outcomes for severe hemophilia patients in the United States.
- In February 2025, Novo Nordisk announced continued investments in next-generation recombinant factor therapies and digital patient support programs aimed at improving prophylactic treatment adherence and quality of life.
Market Segmentation
United States Hemophilia Market, By Disease Type
• Hemophilia A
• Hemophilia B
• Congenital Hemophilia
• Acquired Hemophilia
United States Hemophilia Market, By End-Use Industry
• Hospitals
• Hemophilia Treatment Centers
• Specialty Clinics
• Home Healthcare Settings
United States Hemophilia Market, By Therapy Type
• Clotting Factor Replacement Therapy
• Non-Factor Therapy
• Gene Therapy
• Bypassing Agents
• Desmopressin (DDAVP)
Expert Views:
The United States Hemophilia Market is expected to witness robust growth through 2035, supported by increasing adoption of innovative biologics, expansion of gene therapy, improving access to prophylactic treatment, and growing investments in rare disease research. Continued advancements in recombinant factor therapies, AI-enabled patient monitoring, precision medicine, digital health platforms, wearable infusion technologies, and personalized treatment strategies are expected to improve clinical outcomes, patient adherence, and healthcare efficiency. Furthermore, increasing investment in specialty care infrastructure, clinical research, and next-generation genetic therapies is anticipated to create significant growth opportunities for pharmaceutical companies, biotechnology firms, healthcare providers, treatment centers, and research organizations across the United States.
Author: Govind and Krishna By Decisions Advisors and Consulting